News Releases

Date	Title and Summary	View
Nov 18, 2022	CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying Stroke-Inducing Blood Clots
Nov 11, 2022	New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
Nov 10, 2022	New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful LongTerm Improvement in Health-Related Quality of Life
Nov 07, 2022	Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
Nov 03, 2022	Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
Nov 01, 2022	Johnson & Johnson to Acquire Abiomed
Oct 25, 2022	U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Oct 24, 2022	New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
Oct 20, 2022	DePuy Synthes Receives FDA Clearance for TELIGEN™ System
Oct 19, 2022	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2022